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Using the internet to enter data and manage a multinational clinical trial in deep dermal and
3rd degree burns
JT Mitchel1 and O Mills2 1 Target Health Inc., New York, NY and 2 Robert Wood Johnson Medical
School, UMDNJ, New Brunswick, NJ
Global Internet-based clinical trials (G-IBCTs) can offer convenient, cost-effective solutions for
streamlining aspects of the clinical research process. Areas affected by G-IBCTs include study startup,
monitoring, implementation of protocol amendments, medical review of safety data, data manage-
ment, query management, and project management. By decreasing time to database lock, compa-
nies can reduce overall development costs, accelerate the decision-making process and decrease the
time it takes to submit the marketing dossier. The study was a multicenter, multinational clinical
trial designed to evaluate a new debriding agent for the treatment of deep dermal and 3rd degree
burns. Clinical research sites were in the United States, Europe, Eastern Europe, Israel and India.
Wound location was tracked electronically, so at followup visits, the appropriate wound locations
automatically appeared. As new sites were added, the investigator and site personnel registered online
and had rapid access to the Case Report Forms (CRFs). As protocol amendments were approved by
individual countries and individual IRBs, revised CRFs were immediately made available through
a centrally controlled server. The key challenges for the study were: 1) to create a user-friendly
CRF, 2) for the clinical sites to enter the data in a timely manner, and 3) for the monitors to work
closely with the sites to manage the implementation of this new paradigm in clinical research. For
the majority of sites, we were able to monitor enrollment, safety, and key outcome variables in real-
time and quickly intervene if problems arose. These major advantages allowed for an overall suc-
cessful execution of the study. 
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Cosmetics and quality of life
C de Belilovsky,3 B Chadoutaud,2 J Choulot1 and P Msika1 1 Laboratoires Expanscience, Epernon,
France, 2 BC Consulting, Toulouse, France and 3 CDB Consulting, Paris, France
Quality of life (QoL) measurement has become a major endpoint in clinical studies. This concept
gives a central role to the patients. It measures, with specific questionnaires, subjective aspects of
the illness, treatment, satisfaction and well-being. QoL measurement have been included in our
clinical evaluation (open or double-blind vs placebo, under dermatological control) of cosmetic prod-
ucts since many years. This parameter complete the results of the subjective and objective clinical
scores, and boost the evaluation of cosmetic products. QoL can be evaluated using different ques-
tionnaires. For example, 25 questions selected from the VQ dermato QoL questionnaires, have been
used in order to evaluate the contribution of a lipidic emulsion in the management of acne patients
with isotretinoin or the efficacy of a new molecule (5 alpha Avocuta) in face and scalp hyper-sebor-
rhoea. For AD, IDQOL, DFIQ and Eczema severity questionnaires can be used. For melasma, the
specific MELASQOL has been selected. A decrease of the quotations reflects an improvement of
QoL. The negative impact of acne on QoL of young adults, especially for psychic state, auto-per-
ception + self-estime and social relationships has been confirmed. The specific emulsion improved
by 25% all the criteria. For scalp and face hyper-seborrhoea, VQ dermato QoL questionnaire demon-
strated the efficacy of the new molecule with a significant improvement of physical discomfort, daily
activities, social relationship, self-estime and psychological state. For AD, the decreased of the quo-
tations was significantly more pronounced in the groups with emollients (-73%) than in the groups
with steroids alone (-52%). For hyper pigmentation the study is on progress. QoL was significantly
correlated to the severity and improvement of clinical criteria (SCORAD, MASI,..). 
We have shown that cosmetic products play a major role in the improvement of the QoL, a major
endpoint in clinical studies, of patients affected by chronic or relapsing dermatosis. 
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Alefacept for management of steroid-refractory graft-versus-host disease (GVHD) in patients
undergoing allogeneic hematopoietic stem cell transplantation
AA Toor, PJ Stiff, BJ Nickoloff and KB Gordon Oncology Institute, Loyola University, Maywood,
IL
A major obstacle in allogeneic hematopoietic stem cell transplantation is the development of GVHD.
Activated T cells and dendritic cells induce cutaneous GVHD by the release of cytokines and cell
mediated cytotoxicity causing keratinocyte apoptosis. New approaches for steroid-refractory GVHD
are required due to persistant high patient mortality and morbidity. Alefacept is a recombinant fusion
protein that combines the extracellular domain of LFA3 with the Fc portion of IgG1. Alefacept
binds CD2 and induces apoptosis in CD2hi CD45RO+ T cells leading to depletion of memory T cells.
Since GVHD is dependent on activated T cells, we explored the potential use of alefacept in patients
with this disease. Three patients with steroid refractory GVHD (extensive stage chronic, n=2; acute
grade IV, n=1) were treated with alefacept 7.5 mg intravenous (IV) weekly injections. All had failed
second line therapy. Both patients with chronic GVHD achieved a clinical response by week 4. One
patient experienced a marked improvement with decreased pruritus and erythema. The second patient
had more modest, primarily symptomatic improvement. The patient with acute GVHD achieved a
marked improvement with remission after 3 doses of alefacept (2 in week 1 and 1 in week 2). All
patients demonstrated improvement in the histological grade of GVHD after 4 weeks of therapy with
a reduction in infiltrating CD3+ and CD8+ T cells. Importantly, all patients had their corticosteroid
doses reduced following alefacept treatment. Alefacept was well tolerated. One patient had alefacept
held due to an acute infection, but was able to resume therapy after antimicrobial therapy. All patients
had GVHD recur upon discontinuing alefacept. The patient with acute GVHD had recurrence of
treatment-related acute leukemia after discontinuation of therapy. We believe these results indicate
that alefacept may be of therapeutic benefit in patients with steroid refractory GVHD and further
trials using alefacept in this clinical setting are being planned. 
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STAT3 is activated in psoriatic plaques and rapidly reduced following treatment with anti-
TNFα monoclonal antibody, adalimumab
BK Bonish,1 T Patel,1 R Hoffman,2 BJ Nickoloff1 and KB Gordon1 1 Pathology, Loyola University,
Maywood, IL and 2 Abbott Laboratories, Abbott Park, IL
Transgenic mice with constitutively activated STAT3 targeted to keratinocytes (KCs) spontaneously
develop skin lesions resembling psoriasis. STAT3, a transcription factor, regulates a wide variety of
genes in different cell types including KCs and immunocytes, thereby influencing proliferation,
immune and inflammatory functions. To identify a role for STAT3 signaling in human psoriatic
lesions (PP skin), we defined expression profile for activated STAT3 (phosphorylated with nuclear
translocation: PY-STAT3) before, and after treatment with adalimumab, an anti-TNFα mAb. Psori-
atic patients were enrolled in a blinded, placebo controlled trial (n=7). Biopsies were performed from
peri-lesional (PN) skin on day 0, and PP skin at days 0, 2, 7, 28, 84, and immunostained to localize
PY-STAT3, as well as Ki-67 and keratin 16. Treated subjects had significant differences (p<0.01)
from control subjects (n=6) by day 28, in epidermal thickness, Ki-67, and keratin-16, as well as
clinically improved PASI scores. In untreated patients, PY-STAT3 was expressed in suprabasal epi-
dermal KCs from PP skin but not PN skin. PY-STAT3 was also identified in CD68+ mononuclear
cells (i.e. macrophages /dendritic cells) in upper dermis. In patients receiving adalimumab (but not
control subjects) the most prominent reduction in PY-STAT3 was detected in epidermal KCs. As
early as 2 days after therapy, PY-STAT3 expression in suprabasalar KCs declined from 40.6+/-3.6
positive nuclei per high power field to 23.2+/-2.4 (p<0.01), with further decreases at day 7 (15.4+/-
1.6). These reductions in PY-STAT3 occurred after a single dose of adalimumab, and well before
other histological and immunophenotypic changes in KCs. We conclude: (1) STAT3-mediated sig-
naling is activated in KCs, as well as mononuclear cells in PP skin; (2) adalimumab triggers a rapid
decline in epidermal KC expression of PY-STAT3 preceding reduction in mononuclear cells. Thus,
activated STAT3 appears to represent a therapeutic target rapidly reduced by adalimumab. 
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Clinical and pharmacokinetic equivalence of etanercept 25 mg twice weekly and 50 mg once
weekly in patients with psoriasis
B Elewski,1 C Leonardi,2 P van de Kerkhof,3 W Sterry,4 A Wang5 and A Jahreis5 1 University of
Alabama, Birmingham, AL, 2 St. Louis University, St. Louis, MO, 3 University Hospital Nijmegen,
Nijmegen, Netherlands, 4 Humbolt University, Berlin, Germany and 5 Amgen Inc., Thousand Oaks,
CA
Objective: To assess whether conversion of etanercept (ETN) 25 mg twice weekly (BIW) to 50 mg
once weekly (QW) can maintain comparable clinical efficacy and pharmacokinetics (PK) profiles
in patients with psoriasis. Methods: Patients who received 25 mg BIW dosing in the ETN phase 3
studies enrolled in an open-label extension study and received 50 mg QW dosing. A total of 265
patients who enrolled within 15 days of completing one of the phase 3 studies were assessed for
efficacy after 12 weeks of open-label therapy. The primary endpoint was a mean change from base-
line in the Psoriasis Area and Severity Index (PASI). PK data were compared between 25 mg BIW
dosing in a second phase 3 study and 50 mg QW dosing in the extension study. Results: Mean PASI
score improved from 18.43 at baseline of the first study to 5.77 at baseline of the extension study
after treatment with ETN 25 mg BIW. After 12 weeks of ETN 50 mg QW, mean PASI score was
sustained at 5.82, a mean difference of -0.06 (95% CI [-0.40, 0.29]; P=0.76) between the dosing
regimens. Similar sustained improvements were observed in the Dermatology Life Quality Index (0-
30) with mean scores improving from 10.77 at baseline of the first study to 3.13 at baseline of the
extension study to 3.03 at week 12. A similar proportion of patients receiving ETN 25 mg BIW (43%)
and 50 mg QW (38%) achieved a Dermatologist Static Global Assessment of Psoriasis of Clear/Almost
Clear status. Steady-state serum concentrations (ng/mL) were almost comparable after 96 hrs (2,046
for 25 mg BIW vs 2,538 for 50 mg QW) and 168 hrs (1,709 for 25 mg BIW and 1,493 for 50 mg
QW) of treatment. Conclusions: Improvements in disease status achieved using etanercept 25 mg
twice weekly were substantially sustained at a dose of 50 mg once weekly, cutting in half the injec-
tions needed. The pharmacokinetic profile was comparable for both dosing regimens. 
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Epidermal growth factor enhances healing of persistent non-healing skin lesions of pemphi-
gus vulgaris
M Nazemi Tabrizi, C Chams-Davatchi, P NoormohammadPoor, F Safar, F Gorouhi,
H Etemadzadeh and H Ettehadi Department of Dermatology, Razi Hospital, Tehran University of
Medical Sciences, Tehran, Iran
The purpose of this study was to evaluate efficacy of EGF in reducing healing time of persistent
non-healing ulcers in patients with pemphigus vulgaris. In this double blind randomized study, eleven
patients with pemphigus vulgaris were enrolled. An appropriate skin lesion on each side of the body
were selected and received EGF cream (10 µg g-1) in 0.1% silver sulfadiazine cream and 0.1% pure
silver-sulfadiazine cream alone on left and right side respectively. Application of creams continued
until complete healing of lesions. Mean healing time for lesions treated with EGF plus silver sulfa-
diazine was shorter than lesions treated with pure silver-sulfadiazine by 6.2 days (p<0.0001). No
adverse effect was seen during study. Our data suggest that Topical application of EGF can signifi-
cantly reduce healing time of persistent non-healing skin lesions in patients with pempigus vulgaris. 
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Non-invasive evaluation of irritant and allergic contact dermatitis
S Astner,1 E Gonzalez,2 A Doukas,1 F Rius-Diaz1 and S Gonzalez1,3 1 Department of Dermatology,
Wellman Center of Photomedicine, Boston, MA, 2 Contact Dermatitis Unit, Department of
Dermatology, Massachusetts General Hospital, Boston, MA and 3 Dermatology Service, Memorial
Sloan Kettering Cancer Center, New York, NY
Reflectance confocal microscopy (RCM) has been used to describe the histopathological features
of contact dermatitis (ACD and ICD) non-invasively and in vivo. This study was designed to eval-
uate the kinetics of ACD and ICD and to assess the accuracy of RCM for diagnosing ACD. Subjects
were patch-tested with allergens, irritants and controls. Clinical scoring, RCM, transepidermal water-
loss (TEWL) and fluorescence excitation spectroscopy (FES) were performed at variable time points.
Stratum corneum disruption, spongiosis, exocytosis, vesicle formation and epidermal thickness were
evaluated by RCM. RCM and FES results were analyzed using MANOVA and 2D-ANOVA. Logis-
tic regression analysis was performed on all significant variables to determine the preliminary sen-
sitivity and specificity of RCM data. RCM demonstrates significant differences between ACD and
ICD. SC-disruption, epidermal hyperproliferation and necrosis are hallmarks of ICD and the cuta-
neous disruption induced by irritants more rapidly returns to normal when compared to ACD. ACD
on the other hand shows evidence of vesicle formation as its hallmarks, while both ACD and ICD
showed exocytosis and similar degrees of spongiosis on RCM. The difference in TEWL and Fluo-
rescence intensities between ACD and ICD was statistically significant (p<0.02). Overall, there is
high specificity for all RCM features, ranging from 95.8% - 100%. Significant parameters with high
sensitivity and specificity include spongiosis and exocytosis at the level of spinous and granular layer.
We conclude that non-invasive optical methods such as RCM, TEWL and FES offer significant advan-
tages for longitudinal studies of CD. Our preliminary sensitivity and specificity of individual RCM
parameters prompt the integration of relevant features into diagnostic algorithms. 
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Induction of cellular and molecular changes in actinic keratoses with imiquimod 5% cream
A Torres,1 L Storey,1 W Birmachu,2 R Miller,2 B Bulbulian,2 J Jin,2 S Raghavan,2 S McKane,2
N Gosala2 and H Slade2 1 Dermatology Department, Loma Linda University Medical Center, Loma
Linda, CA and 2 3M Pharmaceuticals, St Paul, MN
A phase II, double-blind, vehicle-controlled, randomized study was conducted to evaluate the cel-
lular and molecular changes in actinic keratosis (AK) lesions treated with imiquimod 5% cream.
Seventeen male subjects with ≥5 AKs on a 25 cm2 area of the balding scalp applied vehicle or
imiquimod 3x/week for 4 weeks. A shave biopsy was taken from 1 AK at study initiation, at treat-
ment weeks 1, 2, and 4, and 4 weeks posttreatment for gene expression analysis. A biopsy was also
taken from a sun-unexposed, non-AK area and from a non-AK, sun-exposed area. Confocal
microscopy was performed on the treatment area as a noninvasive, adjunctive diagnostic procedure.
In order to delineate the mechanism of activity of imiquimod, gene expression analyses were per-
formed on all biopsies taken before and after treatment using Affymetrix® gene chips and real time
reverse transcriptase polymerase chain reaction. The differential gene expression shows that imiquimod
regulates the expression of numerous genes involved in several cellular processes, including recruit-
ment and activation of macrophages, dendritic cells, cytotoxic T cells, and natural killer cells, as well
as activation of apoptotic pathways. Imiquimod reversed the expression of tumor-associated genes
altered by AK by increasing the expression of genes with tumor suppressor activity and decreasing
the expression of genes with tumor proliferative activity. The gene expression changes seen are con-
sistent with the cellular changes observed by confocal microscopy, which showed a normalization
of confocal cellular images. In conclusion, data suggest that the efficacy of imiquimod in AK results
from activation of both innate and adaptive immune responses, resulting in apoptotic as well as cell-
mediated immune destruction of lesions. Imiquimod may also play a role in normalizing sun dam-
age gene expression and cellular morphology. 
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UVA induces immediate and enzyme-independent nitric oxide formation in healthy human
skin leading to NO-specific signalling
A Paunel, A Dejam, S Thelen, M Kirsch, M Horstjann, P Gharini, M Muertz, M Kelm, H de Groot,
V Kolb-Bachofen and C Suschek Department of Immunobiology, Heinrich-Heine-University
Duesseldorf, Duesseldorf, Germany
Many of the local UV-induced responses are influenced by nitric oxide synthase (NOS)-produced
NO, known to play a pivotal role in skin physiology. Besides NOS-mediated NO-production, UVA
radiation will trigger enzyme-independent NO formation in human skin by the decomposition of
photo-reactive nitrogen oxides. We have determined the local concentrations of NO-derived prod-
ucts in human skin and examined the mechanisms of their decomposition after UVA irradiation. Fur-
ther we demonstrate that nonenzymatically produced NO serves as a biological signal. In normal
human skin specimens we find nitrite and S-nitrosothiols at concentrations 25- or 360-fold higher
than those found in plasma. UVA irradiation of human skin leads to immediate high-output forma-
tion of bioactive NO due to photo-decomposition of nitrite and RSNO comparable to that seen with
maximally activated iNOS expressing cells in vitro. Interestingly, the presence of reduced thiols
strongly augmens photo-decomposition of nitrite and is essential for maximal NO release. We demon-
strate that enzyme-independent formed NO leads to significant cGMP formation. In cultured ker-
atinocytes nitrite-derived NO after UVA challenge regulates cell proliferation and differentiation. In
conclusion, enzyme-independent NO formation in human skin represents a physiological signalling
event active in regulating cellular functions. 
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Safety and efficacy of a new biologic agent in the treatment of plaque-type psoriasis
JA O’Daly Astralis LTD, Fairfield, NJ
The substance known as AS210 is a protein extract obtained from cultured amastigotes of Leish-
mania braziliensis, a protozoan parasite responsible for the infectious disease known as leishmani-
asis, endemic in over 80 countries. Serendipitous observations from clinical trials testing Leishma-
nia amastigote extracts as vaccines against the disease indicated that the substance may be effective
in the treatment of psoriasis. The double-blind, randomized, placebo-controlled study to be reported
here was designed to investigate the safety and efficacy of 3 dose levels of AS210, intramuscularly
administered 6 times over 12 weeks, in the treatment of moderate to severe plaque-type psoriasis. A
total of 130 psoriasis patients were randomized to 4 balanced treatment groups. Study endpoints
included standard measures of psoriasis symptom scoring and global severity assessments, as well
as serological and immunological assays designed to help understand the possible mechanism of
action of the drug. Punch biopsies were obtained for histopathological examination and for analy-
sis of peripheral blood leukocyte activity. 
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Randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the
treatment of moderate to severe facial seborrheic dermatitis
E Warshaw,1,2 J Wohlhuter,1,2 D Drake,2 S Zeller,2 R Wenner,1,2 S Bowers,1 J Schultz2 and
A Parneix-Spake3 1 Dermatology, Mpls VAMC, Minneapolis, MN, 2 University of Minnesota,
Minneapolis, MN and 3 Novartis Pharmaceuticals, East Hanover, PA
Seborrheic dermatitis is an inflammatory skin condition commonly treated with topical corticos-
teroids. Pimecrolimus cream 1% inhibits T-cell cytokine production and therefore may be benefi-
cial in its treatment. This study was designed to compare the efficacy and safety of twice daily pime-
crolimus vs. vehicle for 4 weeks in moderate to severe facial seborrheic dermatitis. This
investigator-initiated, double-blind, parallel-group, vehicle-controlled clinical trial randomized
subjects with moderate to severe facial seborrheic dermatitis to either pimecrolimus (P) or vehicle
(V), used twice daily for 4 weeks. Clinical assessments [erythema (0-3) and scaling (0-3) combined
for a total score (0-6)] were performed at week 0, 2 (W2), and 4 (W4). Primary efficacy outcome
was change from baseline in total score at W4. This was analyzed using a two-sample t-test for both
intent-to-treat (ITT) and per protocol (PP) populations. 96 adults were randomized (n=47 P; 49 V).
At W4, the mean change from baseline was -3.7 in the pimecrolimus group vs. -3.3 for the vehicle
[ITT: p=0.1913; 95% CI for difference (-0.195, 0.961)]. PP analysis (n=41 P; 46 V) indicated a sig-
nificant difference between groups [mean changes of -3.9 for pimecrolimus vs. -3.2 for vehicle; p =
0.0156; CI (0.129, 1.197)]. This superiority of pimecrolimus observed at W4 was seen as early as 2
weeks of treatment [ITT: p=0.0062; CI (0.132, 0.777); PP: p=0.0012; CI (0.410, 1.593)]. No drug-
related serious adverse events were reported in either group. Most frequent drug-related adverse
events were local, mild and transient reactions (P: 26%; V: 12%). The results suggest that pime-
crolimus cream 1% is an effective treatment alternative for moderate to severe seborrheic dermati-
tis of the face. 
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Cutaneous vaccinia responses in individuals with and without previous smallpox vaccination
EL Simpson,1 E Hammarlund,2 M Hercher,3 JM Hanifin1 and MK Slifka2 1 Dermatology, Oregon
Health & Science University, Portland, OR, 2 Vaccine and Gene Therapy Institute, Oregon Health
& Science University, Portland, OR and 3 School of Medicine, Oregon Health & Science
University, Portland, OR
Smallpox vaccinations were no longer needed after smallpox was eradicated in 1978. Approximately
40% of the U.S. population is unvaccinated, and the remainder have unknown levels of immunity,
though we recently showed that most retain significant long-term antiviral activity (Nature Med.
2004, 9:1131). Under threat of bioterrorism, smallpox vaccinations were reinstituted in December,
2002. Our objectives were as follows: 1. To measure duration, course and features of cutaneous vac-
cinia responses, comparing subjects previously vaccinated (PV) with newly vaccinated (NV). 2. To
compare humoral and cellular immune responses in the PV and NV groups. 3. To compare skin and
viral effects of betadine ointment application. 26 volunteers working in the OHSU Vaccine Center
(PV=17, NV=9) underwent vaccinia scarification using standard protocols. Close-up photography
with a standard measuring strip was performed q 3d for 30 days and scored by 2 dermatologists
blinded to subject vaccination history. Humoral and cellular immunological parameters were meas-
ured. The mean time since last vaccination in the PV group was 33.2 years. The mean time to max-
imal pustule formation was shorter in the PV group (6.6 days) vs. NV (9.6 days, p<0.001).  Maxi-
mum erythema diameter was smaller in the PV group (1.9 vs. 3.9 cm, p<0.001)).  The PV group had
almost 4-fold larger antibody responses 30 days post-vaccination. Betadine reduced viral shedding
but not skin responses. In conclusion, smallpox vaccination reactions in PV have reduced duration
and severity when compared to NV individuals. These findings provide a clinical correlate to the
recent data showing retained antiviral immunity even in individuals vaccinated many years previ-
ously. Physician familiarity with variations in vaccinia responses will improve investigation and man-
agement of smallpox vaccinations. 
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Pilot study of the effects of a 1% genistein ointment in PUVA-treated psoriasis patients
EQ Trokhan, H Wei and M Lebwohl Dermatology, Mount Sinai Hospital, New York, NY
There is an increased risk of squamous cell carcinoma and malignant melanoma associated with
long-term psoralen plus UVA (PUVA) therapy. We have previously shown in hairless mice that genis-
tein, a major isoflavone in soybeans and a specific inhibitor of protein tyrosine kinase, can protect
against PUVA-induced skin thickening, erythema, and DNA damage, and thus, possibly PUVA-
induced carcinogenesis. In this pilot study, we assessed the photoprotective effects of genistein on
PUVA treated psoriatic patients. In two patients, the minimal phototoxic dose (MPD) was meas-
ured, with and without application of a 1% genistein ointment. In both patients, the MPD was greatly
increased after application of genistein, without noticeable side effects. We also examined if genis-
tein inhibited the beneficial effects of PUVA. In four PUVA- treated patients, three different psori-
atic plaques were chosen and assigned to receive either: 1) application of a 1% genistein ointment
one hour prior to UVA irradiation, 2) application of a vehicle one hour prior to UVA irradiation, or
3) normal PUVA therapy. Over a course of 5 months, all psoriatic lesions in each patient improved,
showing decreased erythema, thickness, and scaling. This pilot study shows that genistein allows
for the use of higher UVA dosing during PUVA therapy, which could permit for more rapid improve-
ment of skin lesions and shorter treatment periods. This study also shows that genistein does not
inhibit the beneficial effects of PUVA. Although additional studies will be necessary, the routine use
of genistein with long-term PUVA therapy may prevent the associated increased risk of squamous
cell cancer and melanoma. Further clinical trials with larger treatment groups are currently being
performed.
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Dendritic cell-based immunotherapy for cutaneous T-cell lymphoma (CTCL)
LJ Geskin,1 AA Kingston,1 K Dixon,1 P Kalinski,2 T Whiteside3 and LD Falo1 1 Dermatology,
University of Pittsburgh, Pittsburgh, PA, 2 Surgery, University of Pittsburgh, Pittsburgh, PA and 3
IMCPL, University of Pittsburgh Cancer Institute, Pittsburgh, PA
Phase I/II clinical trials of dendritic cell (DC)-based immunotherapies for patients with CTCL are
ongoing at our institution. Our approach utilizes autologous tumor cells as a source of antigen and
autologous DCs polarized to induce durable Th1-type immune responses. We demonstrate that func-
tional DCs can be consistently generated from Sezary Syndrome patients in sufficient numbers, and
that co-culture or fusion of DCs with tumor cells results in high efficiency of antigen transfer. DC1
polarization with cytokines (IL-1β, TNF-α, IFN-γ, IFN-α and poly I-C) induces maturation and high
level IL-12 production and tumor-loaded DC1 stimulate Th1 responses in MLRs. Vaccines gener-
ated for therapy consisted of mature DCs, which expressed CD80, CD83 and CCR7 surface mark-
ers and secreted high levels of IL-12. 60 to 90% of DCs in these vaccines internalized significant
quantities of tumor-derived proteins. The vaccines were delivered intranodally (3-106 DC /vaccine),
rotating one lymph node group per vaccine under ultrasound guidance, and each patient received 2
courses of 4 vaccines administered at weekly intervals and separated by a two-week rest period. To
date, 3 patients have received the vaccine with no adverse effects. Dramatic clinical and immuno-
logic responses were observed, including  ELISPOT assays demonstrating tumor specific CD8+ T
cell responses. The immunologic data are consistent with immunotherapy-induced changes that
correlate with clinical responses in patients treated with the vaccine. 
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EcoNail™ (5% econazole plus 18% SEPA®) nail lacquer in patients with severe onychomy-
cosis: safety, local tolerability, and systemic exposure
TC Chan,1 C Czarniecki,1 W Burrows,2 R Bittker,2 DB Stough,3 GN Lam4 and MH Silverman1 1
MacroChem Corporation, Lexington, MA, 2 PRACS Institute, San Diego, CA, 3 Burke
Pharmaceutical Research, Hot Springs, AR and 4 MicroConstants, San Diego, CA
The primary objectives of this study were to determine the safety and local tolerability of EcoNail
lacquer (formulated with Soft Enhancement of Percutaneous Absorption, SEPA [2-n-nonyl-1,3 diox-
olane]), in comparison to econazole nail lacquer (without SEPA), when applied to all nails in patients
with severe onychomycosis, and to determine the systemic exposure of econazole. EcoNail uses
SEPA as a drug release enhancer to increase the delivery of econazole from the lacquer matrix. The
first segment of the trial was randomized, blinded and controlled, during which patients were treated
twice daily for 6 weeks with either EcoNail or econazole lacquer to all fingernails and toenails. In
the second segment, all patients received EcoNail applied once daily to all nails for an additional 12
weeks. The trial enrolled 18 healthy patients with mycologically confirmed onychomycosis (T. rubrum
and/or T. mentagrophytes) of at least one great toenail. To maximize exposure, effort was made to
enroll patients with severe disease as characterized by complete nail involvement, onycholysis, fis-
suring, etc. Both lacquers were very well tolerated, without clinically important systemic adverse
events or local intolerability related to nails or peri-ungual skin. During the 6-week double-blinded
phase, the safety profile of EcoNail was comparable to that of econazole lacquer. At no timepoint
between 1 and 6 hours following application of doses on Day 1, Week 3, and Week 6 were blood
levels of econazole detectable. Although not formally part of the protocol procedures, clinical pho-
tographs in 5 of the first 14 completed patients (having received either 12 or 18 weeks of EcoNail
treatment) were judged by independent dermatologists to have shown initial signs of nail improve-
ment. EcoNail was well-tolerated, produced minimal systemic exposure to econazole, and warrants
advancement to efficacy trials. 
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Alefacept plus 311 nm narrowband ultraviolet B (NB-UVB) phototherapy in the treatment of
psoriasis
FJ Legat, A Hofer, A Wackernagel, W Salmhofer, H Kerl and P Wolf Dermatology, Medical
University Graz, Graz, Austria
Alefacept (Amevive®), a biological drug interfering with T-cell activation and inducing T-cell
apoptosis, reduces the psoriasis area and severity index (PASI) in patients with moderate to severe
psoriasis. The onset of alefacept‘s anti-psoriatic effect, however, is delayed and in previous studies
PASI reduction >75% is reported to be reached by only 30% of patients after weekly alefacept for
12 weeks. In a half-side comparison we assessed whether additional 311nm NB-UVB phototherapy
could improve therapeutic efficacy of alefacept. Fourteen patients (4F/10M; mean age 48, range 25-
59; PASI >10), were enrolled into the study and received weekly alefacept (7.5 mg, i.v.). Three
times per week patients were additionally treated on a randomly selected body half (left or right side)
with NB-UVB until complete remission (CR), as defined in our study by PASI reduction to values
<3 on that body half. NB-UVB dose was 50% of minimal erythema dose at the start and was increased
depending on erythema reaction to previous treatments. Within an observation period of 12 weeks,
treatment significantly (p<0.001; paired t-test) reduced PASI by a mean of 86 and 69% on NB-UVB-
irradiated and non-irradiated body sides, respectively. However, from week 3 to week 12 PASI was
significantly lower on NB-UVB-irradiated compared with non-irradiated sides (p<0.001, Wilcoxon
signed rank test). At week 12, PASI reduction of >75% was reached by 86% of patients on NB-UVB-
irradiated but only by 36% of patients on non-irradiated body sides (p<0.02; Fisher exact test). Forty-
three percent of the patients reached CR on the body sides treated with NB-UVB while none of the
patients reached CR on the body sides left untreated by NB-UVB (p<0.02). In summary, alefacept
significantly reduced PASI in patients with moderate to severe psoriasis within a 12-week-treatment
period. The addition of NB-UVB is capable of accelerating and improving clearing of psoriatic lesions
by alefacept and the combination of these treatment modalities could become a valuable therapeu-
tic concept. 
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Non steroidal anti-inflammatories and risk of melanoma in high risk patients
CC Ramirez,1 F Ma,1 DG Federman2 and RS Kirsner1 1 Dermatology, University of Miami Miller
School of Medicine, Miami, FL and 2 Internal Medicine, Yale University School of Medicine, VA
Medcial Center, West Haven, CT
We sought to determine in a pilot retrospective cohort, the relationship between the use of non steroidal
anti-inflammatories (NSAIDs) and the incidence, recurrence, and metastases of melanoma in high
risk patients; since results from in vitro, animal and epidemiologic studies have suggested that use
of NSAIDs may reduce melanoma risk. By reviewing computerized medical records at the Miami
VA Medical Center, we retrospectively examined the association between the use of NSAIDs and
melanoma incidence recurrence, and metastases in high risk subjects: white subjects with a previ-
ous histological diagnosis of cutaneous melanoma from 1996 to 2003. We evaluated 3 potential out-
comes: the histological diagnosis of a new melanoma, recurrence of a previous melanoma and
melanoma metastasis. Eighty-three subjects with melanoma were included in the analysis. There
was one metastasis (3.6%) among 28 subjects prescribed NSAIDs, while there were 4 new melanomas
(7.3%), 2 melanoma recurrences (3.6%) and 6 metastases (10.9%) among 55 patients not prescribed
NSAIDs. Although no individual outcomes measures reached statistical significance, combining
the 3 measures, these outcome measures were significantly lower in users of NSAIDs compared to
non-users (1 vs. 12, p=0.05). After adjustment for age and tumor Breslow depth of invasion, NSAIDs
use was associated with significantly lower rates of melanoma outcome measures (OR=0.08, 95%
CI=0.01-0.77; p=0.03). The results of this pilot retrospective cohort study suggest a potential for
chemoprevention of melanoma with NSAIDs among patients at high risks; however, further prospec-
tive studies are needed to help elucidate the role of NSAIDs in chemoprevention of melanoma. 
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Clinical utility of flow cytometry of cutaneous T and B cell lymphoma lesions
S Oshtory,1 N Apisarnthanarax,1 AC Gilliam,1 KD Cooper1 and HJ Meyerson2 1 Case Cutaneous
Oncology Program, Case Western Reserve University/University Hospitals of Cleveland,
Cleveland, OH and 2 Department of Pathology, Case Western Reserve University/University
Hospitals of Cleveland, Cleveland, OH
Flow cytometry is a well-established technology that has become a routine tool for the diagnosis of
hematopoietic neoplasms involving peripheral blood, lymph node, and bone marrow.  To analyze
the usefulness of flow cytometry for the diagnosis of cutaneous lymphoid lesions, we analyzed
eight millimeter skin punch biopsies from twenty-three patients with atypical lymphoid infiltrates.
Eight cases, with a prior equivocal diagnosis of cutaneous T cell lymphoma, demonstrated a T cell
abnormality by flow cytometry. All cases were CD4+ except one that lacked expression of both
CD4 and CD8, and most were CD26+ (5/6) and CD7- (6/8). Decreased CD3 expression was observed
in four cases, and in each of these the cells were also CD7-. Two cases were CD30+ and both were
CD7-. Although gene rearrangement (2 cases), and tissue immunoperoxidase evidence of pan T cell
marker loss (5 cases), strengthened the diagnosis where histology was non-diagnostic, flow cytom-
etry demonstrated T cell abnormalities in 8/8 cases, indicating greater sensitivity. Six patients showed
monotypic surface light chain expression consistent with a B cell lymphoma by flow cytometry. Flow
cytometric phenotyping augmented histology such that three cases were classified as large B cell
lymphoma, one as follicular lymphoma, and two as chronic lymphocytic leukemia. Two additional
cases were classified as leukemia cutis through characteristic flow cytometry. A reactive histology
was present in seven cases which was congruent with that observed by flow cytometry. In summary,
tissue flow cytometry of cutaneous lymphoid infiltrates is useful for documenting clonality and sub-
classification of B cell lymphomas, and for its sensitivity in detecting abnormalities in T cell lym-
phomas, resulting in clarification of non-diagnostic histology. 
125:1 JULY 2005 ABSTRACTS      A5
928
Effect of substance P on production of interleukin-12 and interferon-γ in peripheral blood
mononuclear cells of patients with chronic severe atopic dermatitis
H Kang,1 Y Park2 and H Kim2 1 Department of Dermatology, St. Paul’s Hospital, College of
Medicine, The Catholic University of Korea, Seoul, South Korea and 2 Dermatology, Kangnam St.
Mary’s Hospital, Seoul, South Korea
Recently SP positive nerve fibers expressing increased IL-12 and elevated level of this neuropeptide
have been reported in AD patients. This study was designed to examine the effect of SP and its frag-
ment on the production of IL-12 and IFN-γ from peripferal blood mononuclear cells (PBMCs)in
chronic severe atopic dermatitis (AD) patients. We aimed to establish whether this neuropeptide acted
on PBMCs to affect these cytokine release and to establish neuro-immunomodulatory effects in
chronic severe AD patients. The effects of SP and SP fragment on the production of IL-12 and IFN-
γ in Staphylococcus aureus Cowan I strain stimulated PBMCs cultures for 24 hours were analysed
in fifteen chronic severe AD patients, and non-atopic individuals as a control by enzyme-linked
immunosorbent assay. The amount of IFN-γ mRNA in the stimulated PBMCs was analysed by reverse
transcription-polymerase chain reaction. Base cytokine profiles of AD patients showed significantly
decreased IL-12 and IFN-γ than non-atopic controls, respectively. In atopic dermatitis patients, SP
and SP4-11 had a significant enhancing effect on both IL-12 and IFN-γ at the concentration of 10-
8M and 10-6M compared to other low concentrations. In compared with non-atopic controls, 10-8M
and 10-6M SP showed significant percentage enhancing effect on both cytokines, but these IL-12 and
IFN-γ up-regulatory effects of SP and SP4-11 were reversed by spantide, a SP antagonist. In con-
trast, SP1-4 fragment didn’t show any specific cytokine production. Also IFN-γ mRNA expression
was pronounced at 10-8M and 10-6M SP. These data may suggest that SP and SP4-11, carboxyl ter-
minal of SP, may involve in the immunomodulation of chronic severe AD patient by regulating IL-
12 and IFN-γ production directly or indirectly. But SP1-4, amino terminal of SP, has no modulatory
effect on the cytokine production of AD patients. 
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Bcl-2 expression and caspase-3 expression in NIH 3T3 cells and Melan-A melanocytes after
ultraviolet B irradiation
K Whang, S Park, B Rho and S Yoon Department of Dermatology, Collage of Medicine,
Soonchunhyang University, Seoul, South Korea
Apoptosis, or programmed cell death, is a genetically regulated, cellular suicide mechanism that
plays a crucial role in development as well as in the maintenance of homeostasis. Ultraviolet light(UV)
irradiation is one of representative apoptotic stimuli.  The proto-oncogenes Bcl-2 has emerged as
important regulators of the apoptotic form of cell death. And the caspase group of protease is essen-
tial for the apoptosis. NIH 3T3 cells and Melan-A melanocytes were irradiated with increasing doses
of UVB and analyzed for an apoptotic mechanism using a RT-PCR and western blotting analysis.
Our data showed that the level of Bcl-2 in both cell lines gradually decreased with increasing doses
of UVB, and the level of caspase-3 in both cell lines gradually increased with increasing doses of
UVB.
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An open-label phase I clinical study to assess the safety of PI-0824 in patients with pemphigus
vulgaris
VP Werth,1,2 BE Strober,3 M Connolly,4 N Korman,5 D Greenstein,6 J Fantasia,7 R Kalish8 and
G Anhalt9 1 Department of Dermatology, University of Pennsylvania, Philadelphia, PA, 2
Dermatology, Philadelphia V.A. Medical Center, Philadelphia, PA, 3 Dermatology, New York
University, New York, NY, 4 Dermatology, University of California San Francisco, San Francisco,
CA, 5 Dermatology, Case Western, Cleveland, OH, 6 Clinical Research, East Coast Clinical
Research, Salisbury, MA, 7 Oral Medicine, Long Island Jewish Hospital, New Hyde Park, NY, 8
Dermatology, SUNY Stony Brook, Stony Brook, NY and 9 Dermatology, Johns Hopkins, Baltimore,
MD
An open-label phase I study was conducted at 8 centers to assess the safety of desmoglein-3 syn-
thetic peptide (186-204) (PI-0824), in patients with PV requiring daily corticosteroid therapy. Bio-
logical responses, including anti-desmoglein 3 (Dsg3), and the number of Dsg3 specific CD4 T cells,
were evaluated for possible early indication of biological activity. IgG subsets IgG1 and IgG4 spe-
cific for Dsg3 were also evaluated. Peptimmune, Inc., Cambridge, MA, has developed PI-0824, the
immunodominant T-cell epitope of Dsg3, as a specific peptide immunotherapy for the treatment of
PV. PI-0824 is a synthetic peptide homologous to a portion of the human Dsg3 molecule. The goal
of infusion with tolerizing doses of PI-0824 is to selectively suppress the production of anti-Dsg3
antibodies through inactivation of and/or deletion of disease-associated CD4 T-cells. A total of 17
patients, in 3 groups of up to 6 patients, each received two IV infusions of 0.4, 2.0, or 10.0 mg/kg
PI-0824 separated by 7 days. No serious adverse events (SAEs) or infusion-associated reactions
(IARs) were reported. A total of 4 disease flares were experienced, 2 prior to treatment with study
drug, and 2 one to 5 months post-treatment. No significant changes in anti-Dsg3 antibody titers
were noted from pre-treatment levels. No appreciable changes in anti-Dsg antibodies were noted,
but the duration of therapy may not have been long enough to see sustained effects on antibody pro-
duction. Future studies will evaluate the role of longer-term treatment, as well as further dose rang-
ing investigations. 
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The anti-inflammatory action of methotrexate. The effect on expression of cell adhesion and
activation molecules in psoriasis
M Torres-Alvarez,2,1 C Fuentes-Ahumada,2,1 J Castanedo-Cazares2,1 and B Moncada2,1 1
Dermatology, Facultad de Medicina Universidad Autonoma de San Luis Potosi, San Luis Potosi,
San Luis Potosi, Mexico and 2 Dermatology, Hospital Central Dr. Ignacio Morones Prieto, San
Luis Potosi, San Luis Potosi, Mexico
The mechanism of action of methotrexate (MTX) in psoriasis has not been elucidated. We investi-
gated the expression of cell adhesion and activation molecules in skin from patients with psoriasis,
before and after treatment with MTX (12 mg/week, eight week times). The expression of ICAM-1,
VCAM-1, E-selectin was studied, as well as CD4, CD8 and CD69 by double-immunostaining. Skin
samples prior to therapy showed a moderate to severe lymphocyte inflammatory infiltrate with pos-
itive staining for ICAM-1, VCAM-1 and CD4+. In addition, blood vessels showed expression of E-
selectin and VCAM-1. After eight weeks of MTX therapy, the cell infiltrate was reduced, as well as
the expression of cell adhesion molecules; the main cell infiltrate were CD8+. They were positive
for the early activation antigen CD69. This later fact is not clear; it could represent persistent T cell
activation, and suggests a role for this molecule in the inflammatory process in psoriasis. Since MTX
discovery, this drug has been considered as a cytotoxic-antineoplastic, but the findings shown here,
may explain its effects in diverse inflammatory/autoimmune diseases aside from its cytotoxic effects. 
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Topical DNA repair enzymes can prevent polymorphous light eruption
A Hofer,1,2 FJ Legat,1,2 A Wackernagel,1,2 H Kerl2 and P Wolf1,2 1 Department of
Photodermatology, Medical University, Graz, Austria and 2 Department of Dermatology, Medical
University, Graz, Austria
Polymorphic light eruption (PLE) is a common photodermatosis caused by ultraviolet radiation
(UVR). This study was designed to assess the preventive effect of a sunscreen and topical DNA repair
enzyme-containing after-sun lotion in PLE. A SPF 30 sunscreen (chemical and physical UV filters),
an after-sun lotion containing liposomal encapsulated micrococcus luteus lysate with endonuclease
activity and photolyase (active AS), and an after-sun placebo formulation (without DNA repair
enzymes) (placebo AS) were kindly provided for this study by ATEIA AG (Vaduz, Liechtenstein).
Fourteen PLE patients (13f; 1m; aged 21-65y) were enrolled. On day 1, the individual minimal ery-
thema dose (MED) of solar-simulated UVR (xenon arc source, Oriel Corp. Darmstadt, Germany)
was assessed. From day 2 to 5, 0.75 individual MED exposures (increased by 0 to 25% per expo-
sure) were given to a total of four 5-by-5 cm skin test fields on symmetrically located, individual
PLE predilection sites. The test fields were treated in randomized and double-blinded fashion either
with SPF30 sunscreen 20 min before UVR exposure, active AS or placebo AS (each at 2mg/cm2)
immediately after UVR exposure, or left untreated. Sixty minutes after UVR exposure all test areas
were treated with visible light (400-450nm, 10J/cm2) to activate the photolyase DNA repair mech-
anism. The photo tests produced PLE symptoms in 86% (12/14) of unprotected, 0% (0/14) of sun-
screen-protected (p<0.0001), 43% (6/14) of active AS-treated (p<0.05), and 71% (10/14) of placebo
AS-treated test fields (p=ns vs. unprotected test fields, Fisher exact test). In addition, the determi-
nation of specific outcome scores (0 to 4) revealed that diseased area, infiltration, and itching was
reduced by 37% (p<0.05) and 58% (p<0.01); 26% (p, ns) and 44% (p<0.02); and 37% (p, ns) and
77% (p<0.01) comparing placebo AS- and active AS-treated vs. untreated test fields, respectively.
These results suggest that DNA damage is a trigger of PLE and the use of sun care preparations con-
taining DNA repair enzymes may be clinically useful for PLE patients. 
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Transcriptonal profiling of the epidermal response to ultraviolet radiation
CL Tock,1 LR Turner,1 P Batra,1 S Coelho,2 SA Miller,2 J Beer,2 M Radonovich,3 JN Brady,3
ML Turner1 and JC Vogel1 1 Dermatology Branch, NCI, Bethesda, MD, 2 CDRH/OST, FDA,
Rockville, MD and 3 Core Microarray Facility, NCI, Bethesa, MD
In this pilot study, we use oligonucleotide microarrays to measure the effect of increasing doses of
solar-simulated UVR (ssUVR) and UVA on global gene expression in human skin. Healthy volun-
teers (n=6) with Fitzpatrick skin type 2 were exposed to ssUVR and UVA doses that correlated with
individual minimal erythema dose (0.2MED, 1MED, 2MED). Modified 4mm shave biopsies of the
exposed epidermis and an unexposed control were collected 24 hours after exposure. Epidermal sam-
ples were processed and applied to Affymetrix HU133A genechips per the manufacturers recom-
mendations. Microarray data was normalized to the individual unexposed control, and compared on
a gene-by-gene basis with a significance level of 0.001. Of the 22283 genes on the microarray, 297
genes were significantly regulated (p<0.001) when comparing ssUVR 2MED to unexposed control.
The UVA 2MED dose demonstrated 32 significant genes including p19, CD86, COLIVa2, LRMP,
Jaw1, IL22 and IL1BCE. The lowest ssUVR dose (0.2MED) produced 35 significant genes with 20
genes designated as hypothetical. The UVA 0.2MED dose demonstrated 36 significant genes with
9 genes designated as transcription factors. When comparing the ssUVR 0.2MED to 2MED responses,
61 genes demonstrate a dose dependent change in transcription including K6, CD24, and COP9.
When comparing the UVA 0.2MED to 2MED, 8 genes are significant, but do not demonstrate pre-
dictable dose dependent change.  These results suggest that epidermal transcriptional responses to
ssUVR are dose dependent. UVA exposures produce less significant changes in transcription, and
do not appear to be dose dependent. Further characterization of these dose related changes could
lead to a better understanding of the pathways involved in maintaining homeostasis after UVR
exposure, and could serve as a foundation to examine the effectiveness of preventive interventions
such as sunscreen and the relevance of in vitro ssUVR cell culture studies. 
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Skin tags and acanthosis nigricans: correlation with overweight and insulin resistance in Mex-
ican children
P Rivera, B Moncada, C Aradillas and B Torres-Alvarez Dermatology, Facultad de Medicina
Universidad Autonoma de San Luis Potosi, San Luis Potosi, San Luis Potosi, Mexico
Hyperinsulinemia, Insulin resistance, overweight and obesity have been increasing in the past few
decades all over the world, in adults but more worrisome in children, leading to increased presence
of the metabolic syndrome. Since there are cutaneous markers of internal disease, we try to assess
whether the presence of acanthosis nigricans and achrocordons (skin tags) are related to abnormal
Body Mass Index (BMI) Waist-Hip ratio(WHR).hyperinsulinemia, hyperglycemia, hyperlipidemia
and insulin resistance throughout the homeostatic model assessment (HOMA. Children were checked
for weight, height, waist and hip circumferences; blood sample for insulin, glucemia, cholesterol,
triglycerides were taken; BMI, WHR, HOMA were calculated as usual. RESULTS: There were 279
children, 133 females, 146 males, 6 to 14 years old, 62.42% with underweight, 23.38% normal weight
and 7.19% with overweight. We found skin tags in 8.79% and acanthosis nigricans in 17.2%, in the
3 nutritional groups. The children with acanthosis nigricans and skin tags showed higher levels in
HOMA, p<0.000001 and p<0.004 respectively ;), cholesterol, p<0.01, triglycerides were also pos-
itively related with acanthosis nigricans. WHR glucose levels age and sex did not show significant
correlation with the cutaneous markers in this study. CONCLUSION: the presence of skin tags and
acanthosis nigricans correlates positively with insulin resistance, even in absence of overweight. The
BMI is an index that encompasses all the tissues not only the adipose one and the proportion of fat
tissue to the others could be different in children, and that could explain the later fact. Health care
providers, educators, as well as parents should take advantage of this knowledge to lead these chil-
dren to obtain proper preventive care 
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A Preliminary Evaluation of the Safety Profile of Onion Extract Gel in Pediatric Use
M Cramblett,1 W Jones,1 S Fariole,1 J Wright,1 M Hauser,1 T Conrad,1 L Eichenfield 2 and
B Hardas1 1 Merz Pharmaceuticals, Greensboro,, NC and 2 Peadiatric Dermatology, Children’s
Memorial Hospital and Health Center, San Diego, CA
A scar management gel (marketed in the US as Mederma®) has been formulated for the pediatric
population (M4K). M4K has been modified by color and fragrance, but contains equal proportions
of therapeutic ingredients Cepalin®, a proprietary onion extract, and allantoin. M4K was assessed
for safety in 51 children aged 2-12. A target scar was selected based on size (≤ 6.5 cm2 for scar from
injury; ≤ 50.0 cm2 for scar from burn) and age (scar resulting from wound incurred ≤ 6 months from
entry). M4K was applied 3 times daily for 8 weeks. Study visits (Week 0, 1, 2, 4, 8) included prod-
uct application in the presence of clinical dermatology staff in order to assess potential post-appli-
cation adverse events as well as cumulative effects of product application. Adverse events were
assessed by clinical dermatology staff and parent/guardian. Preliminary measures of efficacy were
also explored by parent/guardian assessment using visual analog scales (VAS) of scar appearance,
texture, softness, and color at 0, 4, and 8 weeks. Results support the use of M4K in children, with 1
reported adverse event (dryness/peel) that did not result in discontinuation of M4K. Assessment of
scar variables demonstrated significant (p < .001) improvement on all measures from baseline to 4
weeks, baseline to 8 weeks, and from 4 to 8 weeks. Phototoxicity (n=25) and photoallergenicity
(n=10) studies were also performed. M4K did not elicit either phototoxic or photoallergic response
in studied individuals. 
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Results of a phase II study of a human anti-interleukin (IL)-12/IL-23 monoclonal antibody in
the treatment of psoriasis
R Langley,1 M Lebwohl,2 C Leonardi,3 N Yeilding,4 C Guzzo,4 Y Wang,4 L Dooley4 and
GG Krueger5 1 Dalhousie University, Halifax, NS, Canada, 2 Mount Sinai School of Medicine,
New York, NY, 3 St. Louis University, St. Louis, MO, 4 Centocor, Inc., Malvern, PA and 5 University
of Utah Health Sciences Center, Salt Lake City, UT
Psoriasis plaques are infiltrated by immune cells with a type 1 cytokine expression profile suggest-
ing that IL-12 and IL-23,which initiate type 1 responses,may play a pathogenic role.We report the
results of a Phase II study of CNTO 1275,a human monoclonal antibody against the p40 subunit of
IL-12 and IL-23,in the treatment of psoriasis.Safety and efficacy of CNTO 1275 were studied in
321 patients (Pts) with moderate to severe psoriasis in a double-blind, placebo-controlled study.Pts
were randomized to placebo (PBO) or subcutaneous CNTO 1275: X* mg single dose, 2X mg sin-
gle dose, X mg weekly x 4 (4Xmg), or 2X mg weekly x 4 (8Xmg).Pts in the CNTO 1275 groups
recieved an additional dose at week 16 if Physician Global Assessment score ≥3.Pts in the PBO group
received 2X mg of CNTO 1275 at week 20.The proportions (number) of Pts who achieved ≥75%
improvement in the Psoriasis Area and Severity Index score (PASI75) at week 12 in the Xmg, 2Xmg,
4Xmg, and 8Xmg arms were 51.6%(33/64),59.4%(38/64),67.2%(43/64),and 81.3%(52/64),respec-
tively, vs 1.6%(1/64) in PBO(p<0.001 vs PBO). 23.4%(15/64),29.7% (19/64),43.8%(28/64), and
51.6%(33/64) of Pts in these respective groups achieved PASI90 vs 1.6%(1/64) in PBO.CNTO 1275-
treated Pts had significant improvements in quality of life compared to PBO.79.4% of CNTO 1275-
treated Pts experienced at least one AE compared to 71.6% in PBO through the PBO-controlled
portion of the trial.The proportion of Pts with AEs did not increase with dose,and AE frequency in
the 8Xmg group was similar to PBO.Serious AEs were reported in 3.6% of CNTO 1275-treated Pts
and 1.5% in PBO.CNTO 1275 appears highly effective and well-tolerated in the short-term treat-
ment of psoriasis demonstrating the therapeutic potential of targeting IL-12 p40. Additional studies
to evaluate long-term safety and efficacy are warranted.(*X to be disclosed at SID) 
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Polyphenon® E ointments in the treatment of external anogenital warts—completing phase 3
study results
K Beutner,1 S Tatti,2 A Rodriguez Donado,3 C Thielert,4 H Tawfik,4 D Gungor4 and A Mescheder4
1 Solano Clinical Research, Dow Pharmaceutical Sciences, Vallejo, CA, 2 Hospital de Clinicas,
Buenos Aires, Argentina, 3 Hospital de Kennedy, Bogota, Colombia and 4 MediGene AG, Munich,
Germany
Polyphenon® E is a defined extract from green tea leaves, containing a mixture of green tea cate-
chins, particularly (-)-epigallocatechin gallate (EGCG). Two strengths of Polyphenon® E Ointment
were investigated in this second Phase 3 clinical trial for efficacy and safety in the topical treatment
of HPV-induced external anogenital warts (EGWs). Randomized, double-blind, placebo-controlled
trial (CT1018). 50 centers in the USA, Mexico, Latin America, and Romania enrolled 502 male and
female patients ≥18 years of age, with 2-30 EGWs ranging from 12 to 600 mm2 total wart area.
Main study objectives were complete clearance of all (baseline and new) EGWs, recurrence of cleared
warts, safety and tolerability. Polyphenon® E 15% or 10% Ointment or placebo ointment was applied
3 times daily until complete clearance of all EGWs but no longer than 16 weeks. Complete clear-
ance of all baseline and new EGWs were achieved in 57.2% (15% Ointment; p<0.001) and 56.3%
(10% Ointment; p<0.001) of all patients versus 33.7% treated with placebo (Fisher’s Exact test, two-
sided). A wart clearance of more than 50% was observed for 77.6% (15% Ointment) and 71.8% (10%
Ointment) of all patients. Only 6.5% (15% Ointment) and 8.3% (10% Ointment) of the patients who
achieved complete clearance experienced recurring EGWs, and only 3.7% and 8.3%, respectively,
developed new warts during the 12-week follow-up period. Both strengths of Polyphenon® E Oint-
ment demonstrated a good safety profile with the majority of all local reactions assessed as mild or
moderate, supported by an excellent compliance rate of more than 80%. [All figures presented are
based on ITT LOCF analyses]. This study confirmed the results of the first Phase 3 study indicating
that Polyphenon® E Ointment is an efficacious and safe patient-administered treatment for EGWs. 
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Multicenter randomized placebo-controlled clinical trial of dapsone as a glucocorticoid-spar-
ing agent in maintenance phase pemphigus vulgaris
VP Werth,1,4 D Fivenson,6 A Pandya,3 D Chen,7 J Rico,5 J Albrecht1 and D Jacobus2 1 Derm,
UPenn, Philadelphia, PA, 2 Jacobus Pharmaceuticals, Princeton, NJ, 3 Dermatology,
Southwestern, Dallas, TX, 4 VA Hospital, Philadelphia, PA, 5 Fujisawa, Deerfield, IL, 6 Private
practice, Anne Arbor, MI and 7 Connetics, Palo Alto, CA
Uncontrolled series have shown dapsone to be a steroid sparing agent in pemphigus vulgaris (PV).
In this study dapsone was assessed in a randomized placebo-controlled cross-over trial. We report a
5 center, 19 patient trial. Inclusion criteria were biopsy and direct immunofluorescence-proven PV
controlled with glucocorticoids and/or cytotoxics, disease in maintenance phase, and age 18 to 80
years. Patients had at least two unsuccessful tapers of steroids and had 30 days of stable (<10% vari-
ation) steroid dosage of ≥15mg QD or ≥20mg QOD at enrollment. No pulse steroid treatment, pulse
cytoxan, or plasmapheresis within 2 mos of enrollment was allowed. Patients unable to taper glu-
cocorticoids by more than 25% within 4 months were declared a failure, and allowed to switch to
the opposite medication while keeping the blind. Primary outcome was the ability of patients to taper
to ≤7.5mg/day within 1 year of reaching the maximum dosage of the study drug. Blinded clinical
monitors observed the laboratory values. Of the 9 patients on dapsone, 5 succeeded, 3 failed, and 1
was a drop-out. 10 patients were on placebo, 3 succeeded and 7 failed. This primary endpoint favored
the dapsone-treated group, but was not statistically significant (p=0.18). 4 patients who failed on
placebo crossed over to dapsone. Of these, 3 succeeded after crossover and 1 dropped out. We found
that overall 8/11 (73%) of patients receiving dapsone vs 3/10 (30%) receiving placebo reached the
primary outcome of a prednisone dose =7.5 mg/day. Overall side effects included a drug rash (n=1),
paresthesias potentially related to dapsone (n=1), and dyspnea secondary to methemoglobinaemia
(n=1). In conclusion, this trial demonstrates a trend to efficacy of dapsone as a steroid-sparing drug
in maintenance phase PV, and defines parameters for planning future PV trials. 
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Adalimumab clears psoriatic skin lesions
RE Schopf and ER Flores-Wendt Dermatology, Johannes Gutenberg Univ., Mainz, Germany
Psoriasis has shown improvement during anti-tumor necrosis factor (TNF)-alpha treatment. We stud-
ied the effects of the recombinant human IgG1 monoclonal antibody specific for TNF-alpha, Adal-
imumab. We treated 10 patients with psoriasis (3 female, 7 male, aged 25 to 68 years) with a psori-
asis area and severity index (PASI) of 21.1 +/- 2.67 (mean +/- SE). Anti-psoriatic systemic or
UV-treatment was not permitted 4 weeks, topical treatment 2 weeks before or during the study. At
week 0, patients received a loading dose of 80 mg, then 40 mg every other week starting at week 1
until week 11 by subcutaneous injection. Week 12 was the end of observation. Skin biopsies for stain-
ing with H&E, anti-CD4, anti-CD8, HLA-DR, the proliferation marker MIB-1, and the differentia-
tion markers cytokeratin 16, filaggrin and involucrin were taken at weeks 0 and 12. Epidermal
thickness was measured with a microscopic micrometer grid. The patients were also photographed.
We found a diminution of the PASI as follows: weeks 0, 1, 3, 5, 7, 9, 11, 12, respectively: 100%
(week 0), 88.6 +/- 2.2, 55.7 +/- 5.7, 32.1 +/- 6.4, 18.3 +/- 4.4, 14.1 +/- 3.4, 9.4 +/- 2.2 and 5.2 +/-
1.9 (%) (week 12). The epidermal thickness of non-lesional skin was 0.1150 +/- 0.0054, of lesional
skin at week 0: 0.4431 +/- 0.0412, at week 12: 0.1803 +/- 0.0178 mm. At week 12, skin staining
with the different immunologic and proliferation/differentiation markers also tended to normalize.
Treatment was well tolerated; some patients experienced fatigue at the day of injection. Our results
demonstrate that subcutaneous Adalimumab mono-treatment for 12 weeks clears psoriatic skin lesions
almost completely. 
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Etanercept does not effectively treat moderate to severe alopecia areata: an open label study
BE Strober,1 K Siu,1 AF Alexis,2,1 G Kim,1 K Washenik,1 A Sinha3 and JL Shupack1 1 Dermatology,
New York University School of Medicine, New York City, NY, 2 Dermatology, St. Luke’s-Roosevelt
Hospital, New York, NY and 3 Dermatology, Weill Medical College of Cornell University, New York
City, NY
Alopecia areata is a tissue-specific autoimmune disease targeted to the hair follicle. Clinically, it is
characterized by non-scarring alopecia, which can affect the scalp and/or any other hair-bearing sur-
face. Although the pathogenesis of alopecia areata remains incompletely understood, a substantial
body of evidence suggests that T-cell mediated immune responses play an important role. Increased
expression of T-helper type1 (Th-1) cytokines, including, IL-1β, IFN-γ, IL-2, and tumor necrosis
factor-alpha (TNF-α) has been demonstrated in lesional skin of alopecia areata patients and may
contribute to the immune dysregulation that results in hair loss. In this open-label pilot study, we
evaluated the safety and efficacy of etanercept, a TNF-α inhibitor, in the treatment of moderate to
severe alopecia areata, alopecia totalis, or alopecia universalis. After between 8 and 24 weeks of con-
tinuous treatment, significant regrowth of hair was not shown in any of the seventeen subjects treated.
Based on these results, etanercept appears to be ineffective in treating patients with treatment-
refractory, moderate to severe alopecia areata, alopecia totalis, and alopecia universalis. 
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Using teledermatology in the management of post-op breast surgery patients to decrease length
of stay: a pilot study
JD Miller,1 H Hogan,2 S Kogan,2 R Greenes,2 M Ting-Lee,2 J Kvedar1 and R Christian2 1
Dermatology, Harvard Medical School/Massachusetts General Hospital, Boston, MA and 2
Surgery, Harvard Medical School/Brigham and Woman’s Hospital, Boston, MA
Telemedicine uses multi-media communication technologies to remotely diagnose, treat, and mon-
itor patients, conduct consultations, or transfer medical data and education. Modern advances in tech-
nology have brought countless new applications for its use. Teledermatology has been recognized
as one of the most studied fields in telemedicine by the Agency for Healthcare Quality and Research.
In the United States, breast cancer is the most common solid tumor and the second largest cause of
cancer related deaths in women. It is estimated that 6.2 billion dollars are spent in the US each year
on treatment of breast cancer.  Average length of stay (LOS) for breast cancer surgery patients is
approximately three days.  Most of this post-operative care is dermatological-centering on wound
healing, topical skin care and pain management. Teledermatology offers the opportunity to shorten
this stay, increase patient satisfaction and decrease overall costs, to both the patient and the care-
giver. A pilot study was conducted to determine the safety, feasibility, and cost effectiveness of post-
operative management of breast surgery patients via a live-interactive teledermatology system. We
hypothesized that teledermatology would decrease hospital stay and cost of care, maintain safety,
and improve patient satisfaction. A prospective randomized controlled trial of 50 patients was con-
ducted, 25 serving as controls and 25 receiving intervention. Our results demonstrated a decrease in
length of stay in the telemedicine intervention group. Also, we found a 5% direct cost saving per
day for the intervention group. This innovative use of communication technologies answers the needs
of several factions by maximizing patient communication and facilitating shortened hospital stays.
It can be used as a model in other disease states as it proved safe and effective in this study. 
942
Silicon phthalocyanine (Pc 4) photodynamic therapy for the treatment of pre-malignant and
malignant skin conditions: an update
ED Baron,1 K Hanneman,1 HM Scull,1 A Hsia,1 T McCormick,1 NL Oleinick,2 M Kenney3 and
KD Cooper1 1 Dermatology, University Hospitals at Case Western Reserve University, Cleveland,
OH, 2 Radiation Oncology, University Hospitals at Case Western Reserve University, Cleveland,
OH and 3 Biochemistry, University Hospitals at Case Western Reserve University, Cleveland, OH
We aim to present recent data in our development of Pc 4 for photodynamic therapy of skin tumors.
Pc 4 is a second generation photosensitizer that is activated by light at 675 nm and induces tumor
cell specific apoptosis, in vitro. Pc 4- PDT of transplanted tumors in mice causes an influx of inflam-
matory cells into the tumor area and induces upregulation of pro-inflammatory cytokines. Pc 4- PDT
induces cures in immunocompetent (BALB/c) but not in immunodeficient (SCID) mice. This indi-
cates a great potential for the topical application of Pc 4 to localized tumor areas for PDT. A Phase
I dose-escalation trial is in progress and the eight subjects (seven with Cutaneous T-Cell Lym-
phoma, one with Squamous Cell Carcinoma ) treated to date demonstrated no significant toxicity.
TUNEL assays performed on punch biopsies (taken 24 hours post Pc4-PDT) have shown increased
levels of apoptosis compared to laser only and untreated controls. Flow cytometry studies are cur-
rently underway to determine selective apoptosis. 
943
Phase I trial of O6benzylguanine (O6BG) and topical BCNU in the treatment of cutaneous T
cell lymphoma
N Apisarnthanarax,1 S Oshtory,1 MS Ke,1 SK Szabo,1 L Liu,2 AC Gilliam,1 SL Gerson,2 GS Wood,3
SR Stevens4 and KD Cooper1,5 1 Dermatology, University Hospitals of Cleveland, Case Western
Reserve University (CWRU), Cleveland, OH, 2 Medicine, CWRU, Cleveland, OH, 3 Dermatology,
University of Wisconsin, Madison, WI, 4 Amgen, Thousand Oaks, CA and 5 Veteran Affairs Medical
Center, CWRU, Cleveland, OH
BCNU induces cytotoxic interstrand crosslinks in cancer cells through alkylation at the O6 site of
guanine. Some malignancies, including cutaneous T-cell lymphoma (CTCL), have an escape mech-
anism for nitrosourea resistance via the DNA repair protein O6-alkylguanine DNA alkyltransferase
(AGT). O6BG competitively binds and inactivates AGT, thereby preventing DNA damage repair
and allowing cancer cells to become vulnerable to nitrosoureas. In a single-institution clinical trial,
19 mycosis fungoides patients have been treated on a biweekly dosing schedule with O6BG (120
mg/m2 IV) followed by low-dose topical BCNU, starting at 10 mg per cycle with dose-escalation
in 3 patient cohorts. The objectives are to determine the MTD and toxicity of this regimen and the
kinetics of AGT depletion in CTCL skin lesions. The MTD has not yet been reached at the 40 mg
BCNU dosing level. Across all doses, this regimen has produced 12 partial responses, and 2 com-
plete responses (Objective response rate =74%). Toxicity has been limited and transient and has
included mostly Grade I/II post-therapy headaches (53%), nausea (37%), and fatigue (37%), and few
cases of contact dermatitis, leukopenia, and anemia. One case of Grade III headache and 2 cases of
cycle-limiting Grade III AST/ALT elevation have occurred. Baseline AGT activity in CTCL lesions
was diminished by a median of 97% at 6 hrs following O6BG infusion and depletion was 100% at
24 hours, but resolved by 1 week to 80% of original AGT activity. The preliminary statistical data
indicate that the area-under-the-curve (AUC) of AGT over 1 week correlates with clinical disease
reduction (p= 0.01, ρ= -0.73). These results demonstrate that intermittent O6BG-potentiated topical
BCNU is well-tolerated and is capable of producing clinical response in CTCL. 
944
Open-label study of alefacept in the treatment of palmoplantar psoriasis
D Pearce and S Feldman Dermatology, Wake Forest University School of Medicine, Winston Salem,
NC
Psoriasis is a complex disease with several distinct clinical variants. Of these, the palmoplantar sub-
type is notoriously difficult to treat.  PPP is also associated with considerable disability in may of
those afflicted. We plan to present data from a Phase IV trial designed to asses the efficacy and
safety of alefacept in patients with PPP. This is a 16 week open label study of which data collection
is currently underway. Patients will be initially treated with 15 mg/week of alefacept as monother-
apy with the ability to increase the dose to 30 mg/week at week 9 if no appreciable clinical response
is evident. Enrollment is expected to be at least 12 subjects. The primary endpoint will be assessed
at week 22 as the percent of subjects achieving 50% improvement in Palmoplantar Psoriasis Sever-
ity Index. Secondary endpoints include percent of subjects achieving Physicians Global Assessment
(PGA) of 0 or 1 (clear or almost clear) at week 22. Quality of life assessments (SF-36 and DLQI) at
22 weeks will also take place. Hopefully, the material presented here will shed light on the ability
of alefacept to safely treat PPP. 
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Interleukin (IL12) blocks a specific subset of transcriptional responses to UVB in epidermal
keratinocytes
M Molenda,3 L Mukkamala1 and M Blumenberg1,2 1 Department of Dermatology, NYU School of
Medicine, New York, NY, 2 Department of Biochemistry & The Cancer Institute, NYU School of
Medicine, New York, NY and 3 Northeastern Ohio Universities College of Medicine, Rootstown,
OH
Interleukin-12 (IL12) is a proinflammatory and immunomodulatory cytokine that plays a critical
role in innate and adaptive immunity by inducing production of interferon-γ and other cytokines.
IL12 was recently shown to block the ultraviolet light-induced immunosuppression important in can-
cer immunosurveillance, cutaneous allergies and inflammation. To characterize the molecular effects
of IL12 in epidermis we used large DNA microarrays and defined the transcriptional changes in
human epidermal keratinocytes 1h, 4h, 24h, and 48h after treatment with IL12, as well as in cells
treated with both IL12 and UVB light. In keratinocytes, IL12 activates STAT3 and STAT4; surpris-
ingly, despite activating these transcription factors, the transcriptional effects of IL12 did not rise
above background levels.  However, pretreatment of keratinocytes with IL12 strongly affected the
transcriptional effects of UVB. Pre-treatment with IL12 enhanced the UVB-mediated regulation of
20 and antagonized the regulation of 263 genes. IL12 synergistically enhanced the induction of
cytokines by UVB.  IL12 antagonized the suppression of cytoskeletal, junctional, metabolic, mito-
chondrial and extracellular matrix proteins, while antagonizing the induction of certain signaling
proteins and RNA processing enzymes. We conclude that the primary immunorestorative cutaneous
role of IL12 comprises of interference with a specific subset of transcriptional effects of UVB irra-
diation.
707
Evaluation of additional mechanisms of anti-CD11a action
R Khattri, T Tran, C Refino, D Danilenko, V Chuahan, S Hurst and W Ouyang Immunology,
Genentech, Inc., South San Francisco, CA
Lymphocyte function—associated antigen-1 (LFA-1) is a leukocyte cell surface marker that binds
to intercellular adhesion molecule-1 (ICAM-1). This interaction is important for T-cell activation,
endothelial transmigration into dermal tissues, and reactivation therein—all key steps in the
immunopathogenesis of psoriasis. Efalizumab, a humanized, recombinant monoclonal antibody
directed against the a subunit of LFA-1 (CD11a) that blocks the interaction between LFA-1 and
ICAM-1, has demonstrated efficacy in adult patients with moderate to severe plaque psoriasis and
has been approved for this indication. The objective of this study was to investigate potential addi-
tional mechanisms of action that may be associated with efalizumab treatment. Murinized M17
(muM17), the murine surrogate of efalizumab, was used to evaluate if additional lymphocyte sub-
sets and activation markers or functions are altered by anti-CD11a treatment in a murine model of
psoriasis. Various lymphocyte subsets from anti-CD11a—treated mice were analyzed for the expres-
sion of integrins involved in lymphocyte homing. The cytokine profile of T cells from treated mice
was characterized to assess T-cell function. Future experiments will address the contribution of the
various components of anti-CD11a toward its inhibitory effects by treating mice with either the Fab
fragment of anti-CD11a, anti-CD11a that lacks Fc receptor binding, or anti-CD11a. Lymphocytes
from these treated mice will be assessed for down-regulation of CD11a expression and for T-cell
functions. Results from these analyses will be presented. 
692
Movement of nerve growth factor and neurotrophins in atopic dermatitis model mouse
K Tokime,1 R Semba,2 Y Kiyofumi3 and H Mizutani1 1 Mie University Faculty of Medicine, Tsu,
Japan, 2 Institute for Developmental Research,Aichi Human Service Center, Aichi, Japan and 3
Hyogo College of Medicine, Hyogo, Japan
Overgrowth of nerve endings in the lesions of atopic dermatitis (AD) has been reported, and the
involvement of neurotrophins (NTs) has been speculated.  Increased nerve growth factor (NGF) in
the AD lesions are suspected as the causative factors for itching, nerve fiber hypertrophy, epidermal
thickening, mastcell degranulation, and cytokines production from T cells.  As the other NT fami-
lies, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4)
have been suspected to be involved in AD.  However, limited sensitivity and specificity of measur-
ing systems for NTs, the biological roles of NTs in AD is still obscure. Here, we investigated expres-
sion of NGF and NTs in the skin lesions of AD model mouse (KIL-18Tg) which skin-specifically
over-expresses IL-18. KIL-18Tg develops AD-like skin lesions without specific antigens or pathogens.
Expression of NGF, BDNF, NT-3, and NT-4 mRNAs was measured by specific RT-PCR.  Protein
expression was measured using the high sensitive sandwich enzyme immunoassay system that we
have developed.  NGFmRNA was highly expressed in the IL-18tg mouse compared with that of
wild type (WT) mouse. In contrast, expression of BDNFmRNA was suppressed in IL-18Tg. NGF
levels in the organ culture supernatant of IL-18Tg skin were significantly elevated from that of WT.
However, those samples in skin homogenate were unclear.  These results observed in antigen non-
specific, pathogen free AD model mouse strongly suggest that involvement of overproduced NGF
in the skin lesions participates development of AD skin lesions. On the other hand, the suppressed
BDNFmRNA expression in the skin lesions implicated involved in some negative feed back system
for AD. 
765
Efficacy of variable pulsed light in the treatment of hypertrichosis in over 100 patients
R Knobler, H Nahavandi and R Neumann Division of Special Dermatology/AKH-7J, Medical
University of Vienna, Vienna, Austria
In order to confirm the initial  observations on the use of Variable Pulsed Light (VPL)(Energist Ltd.,
U.K.) as an alternative to the use of Intense Pulsed Light (IPL) for the treatment of hypertrichosis,
we evaluated the results on 103 consecutive  otherwise healthy treated and untreated volunteers(Skin
Types II-VI): 97 women and 6 men. Treatment was performed with a variable pulsed 610nm light
source with an off delay time of 1ms to 20ms; the spot size was 5cm x 1cm. Clinical evaluation was
performed using the Teach-Screen Monitoring System (Foto-finder, Mediscope, Germany). Prior to
every treatment procedure the area to be treated was covered with a refrigerator cooled (4 Deg. C)
optical coupling gel (Energist Ltd.,U.K.). Determination of fluence used was based on the individ-
ual’s tolerance to pain; this depended to a great extent  on the specific skin type and coarseness.  The
average fluence used was 37J/cm2 (range: 13-48 J/cm2). Eighty six percent of the areas treated
showed hair clearance of over 50%, thirty-four percent showed hair clearance of over 75% while
fifty two percent had clearance between 50 and 75%. The observed side effects included ery-
thema(47%) and leucotrychia (11%); these were minimal and transient and in no patient significant
enough to interrupt treatment. Pigmentary changes were not observed. The Variable Pulsed Light
system used in this study presents itself as a safe and effective method for hair removal due to
hypertrichosis for medical and/or cosmetic indications. 
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